Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ABBOTT LABORATORIESABT · Entity 2314 | VICE PRESIDENT AND CONTROLLER | September 01, 2026 | September 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ABBOTT LABORATORIES
Report date September 01, 2026 · Filed September 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common shares without par valueSEC Table I · non-derivative | Direct | 24,549 |
Ending reported balance
After 2026-09-02 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-09-01 · Tax withholding · Disposed 52 · Balance 24,576 Row 2 · 2026-09-02 · Sale · Disposed 27 · Balance 24,549 |
| Common shares without par valueSEC Table I · non-derivative | IndirectProfit Sharing Trust | 59 |
Reported balance
Holding disclosure · report date 2026-09-01 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 59 F1: Balance in the Abbott Laboratories Stock Retirement Trust as of September 1, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Balance in the Abbott Laboratories Stock Retirement Trust as of September 1, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 02, 2026 Filed Sep 3, 2026 22:11 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 27 | $109.54 | $2,957.58 |
DisclosureSEC source: 0001644207-26-000012 · form4-09032026_100920.xml · nonDerivative · entry 2 MCCOY JOHN A. JR. · CIK 0001644207 · VICE PRESIDENT AND CONTROLLER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,549 Read SEC document |
| September 01, 2026 Filed Sep 3, 2026 22:11 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 52 | $110.36 | $5,738.72 |
DisclosureSEC source: 0001644207-26-000012 · form4-09032026_100920.xml · nonDerivative · entry 1 MCCOY JOHN A. JR. · CIK 0001644207 · VICE PRESIDENT AND CONTROLLER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,576 Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 00:55 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 585 | $115.58 | $67,614.30 |
DisclosureSEC source: 0001644207-26-000007 · form4-03042026_120315.xml · nonDerivative · entry 2 MCCOY JOHN A. JR. · CIK 0001644207 · VICE PRESIDENT AND CONTROLLER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,628 Read SEC document |
| February 27, 2026 Filed Mar 4, 2026 00:55 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 1,142 | $116.26 | $132,768.92 |
DisclosureSEC source: 0001644207-26-000007 · form4-03042026_120315.xml · nonDerivative · entry 1 MCCOY JOHN A. JR. · CIK 0001644207 · VICE PRESIDENT AND CONTROLLER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,213 Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 23:35 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 22,151 | $0.00 Strike: $114.60 | $0.00 |
DisclosureSEC source: 0001644207-26-000002 · form4-02262026_110204.xml · derivative · entry 3 MCCOY JOHN A. JR. · CIK 0001644207 · VICE PRESIDENT AND CONTROLLER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,151 Underlying: Common Shares · 22,151 shares Expires 2036-02-23 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 7,383 on February 24, 2027, 7,384 on February 24, 2028, and 7,384 on February 24, 2029. Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 23:35 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 5,373 | $0.00 | $0.00 |
DisclosureSEC source: 0001644207-26-000002 · form4-02262026_110204.xml · nonDerivative · entry 1 MCCOY JOHN A. JR. · CIK 0001644207 · VICE PRESIDENT AND CONTROLLER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,355 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| September 01, 2025 Filed Sep 3, 2025 21:39 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 79 | $132.66 | $10,480.14 |
DisclosureSEC source: 0001415889-25-023588 · form4-09032025_090946.xml · nonDerivative · entry 1 MCCOY JOHN A. JR. · CIK 0001644207 · VICE PRESIDENT AND CONTROLLER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,982 Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 00:39 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 562 | $138.17 | $77,651.54 |
DisclosureSEC source: 0001415889-25-006768 · form4-03052025_120309.xml · nonDerivative · entry 2 MCCOY JOHN A. JR. · CIK 0001644207 · VICE PRESIDENT AND CONTROLLER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,061 Read SEC document |
| February 28, 2025 Filed Mar 5, 2025 00:39 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 1,096 | $135.87 | $148,913.52 |
DisclosureSEC source: 0001415889-25-006768 · form4-03052025_120309.xml · nonDerivative · entry 1 MCCOY JOHN A. JR. · CIK 0001644207 · VICE PRESIDENT AND CONTROLLER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,623 Read SEC document |
| February 25, 2025 Filed Feb 27, 2025 23:17 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 15,040 | $0.00 Strike: $135.42 | $0.00 |
DisclosureSEC source: 0001415889-25-005894 · form4-02272025_110224.xml · derivative · entry 3 MCCOY JOHN A. JR. · CIK 0001644207 · VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,040 Underlying: Common Shares · 15,040 shares Expires 2035-02-24 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 5,013 on February 25, 2026, 5,013 on February 25, 2027, and 5,014 on February 25, 2028. Read SEC document |
| February 25, 2025 Filed Feb 27, 2025 23:17 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 4,038 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-005894 · form4-02272025_110224.xml · nonDerivative · entry 1 MCCOY JOHN A. JR. · CIK 0001644207 · VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,719 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| September 04, 2024 Filed Sep 4, 2024 23:52 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 27 | $114.83 | $3,100.41 |
DisclosureSEC source: 0001415889-24-022826 · form4-09042024_100931.xml · nonDerivative · entry 2 MCCOY JOHN A. JR. · CIK 0001644207 · VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,681 Read SEC document |
| September 01, 2024 Filed Sep 4, 2024 23:52 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 52 | $113.27 | $5,890.04 |
DisclosureSEC source: 0001415889-24-022826 · form4-09042024_100931.xml · nonDerivative · entry 1 MCCOY JOHN A. JR. · CIK 0001644207 · VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,708 Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 00:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 472 | $118.50 | $55,932.00 |
DisclosureSEC source: 0001415889-24-006409 · form4-03052024_120333.xml · nonDerivative · entry 2 MCCOY JOHN A. JR. · CIK 0001644207 · VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,760 Read SEC document |
| February 29, 2024 Filed Mar 5, 2024 00:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 921 | $120.05 | $110,566.05 |
DisclosureSEC source: 0001415889-24-006409 · form4-03052024_120333.xml · nonDerivative · entry 1 MCCOY JOHN A. JR. · CIK 0001644207 · VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,232 Read SEC document |
| February 21, 2024 Filed Feb 23, 2024 22:35 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 16,563 | $0.00 Strike: $116.98 | $0.00 |
DisclosureSEC source: 0001415889-24-005101 · form4-02232024_100234.xml · derivative · entry 3 MCCOY JOHN A. JR. · CIK 0001644207 · VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,563 Underlying: Common Shares · 16,563 shares Expires 2034-02-20 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 5,521 on February 21, 2025, 5,521 on February 21, 2026, and 5,521 on February 1, 2027. Read SEC document |
| February 21, 2024 Filed Feb 23, 2024 22:35 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 4,407 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-005101 · form4-02232024_100234.xml · nonDerivative · entry 1 MCCOY JOHN A. JR. · CIK 0001644207 · VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,153 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 22:50 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 2,071 | $0.00 Strike: $103.18 | $0.00 |
DisclosureSEC source: 0001415889-23-013035 · form4-09062023_100916.xml · derivative · entry 3 MCCOY JOHN A. JR. · CIK 0001644207 · VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,071 Underlying: Common Shares · 2,071 shares Expires 2033-08-31 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 690 on September 1, 2024, 690 on September 1, 2025, and 691 on September 1, 2026. Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 22:50 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 531 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-013035 · form4-09062023_100916.xml · nonDerivative · entry 1 MCCOY JOHN A. JR. · CIK 0001644207 · VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,746 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.